Fintech PR
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
MELBOURNE, Australia and DRESDEN, Germany, March 18, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organisation (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB.
QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens. Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.
QDOSE® supports dosimetry calculations using planar imaging, tomographic imaging, single/multi time point imaging and hybrid combinations. QDOSE® incorporates additional tools for attenuation and background correction. The QDOSE® platform will be integrated with Telix’s artificial intelligence (AI) products as an accessible tool for clinicians and third-party commercial drug developers. QDOSE® has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is Conformité Européenne (CE) marked for clinical use within the European Union (EU).
Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “In nuclear medicine, dosimetry analysis is used to calculate the absorbed dose of radiation received by different parts of the body. Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis. QDOSE® has an excellent performance track record and we are committed to positioning QDOSE® as a new industry standard in dosimetry analysis.”
The arms’ length up-front transaction consideration is non-material. Telix will pay undisclosed product royalties and fees on product sales.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA,[1] by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3] Telix’s miniaturised surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, has attained a marketing authorisation in the U.S., having been registered with the FDA and has attained a CE Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes. With the exception of Illuccix® and SENSEI® as noted above, no Telix product has received a marketing authorisation in any jurisdiction.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Illuccix® and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
|
[1] Telix ASX disclosure 20 December 2021. |
|
[2] Telix ASX disclosure 2 November 2021. |
|
[3] Telix ASX disclosure 14 October 2022. |
Logo – https://mma.prnewswire.com/media/1920208/4598441/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/qdose-platform-partnership-for-personalised-dosimetry-in-radiopharmaceutical-therapy-302092075.html
BEIJING, Dec. 19, 2024 /PRNewswire/ — The 2024 Beijing Forum on Swift Response to Public Complaints opened in the Chinese capital on Wednesday, where leading global academics and representatives share their insights and explore strategies for modernizing urban governance.
With the theme of “Modernizing for People-Centered Urban Governance,” the two-day event from Wednesday to Thursday has gathered more than 700 participants, including domestic and international guests, representatives from China’s Hong Kong Special Administrative Region (SAR), Macao SAR and the Taiwan region, scholars from universities and representatives of grassroots workers.
Beijing is a city with a profound history and rich cultural heritage, as well as a vibrant, modern international metropolis. Covering an area of over 16,000 square kilometers, it has a permanent population of 21.858 million.
In response to urban governance challenges, Beijing launched the swift response to public complaints reform in 2019, providing rapid responses and efficient handling of citizens’ concerns through the 12345 Citizen Service Hotline.
Over the past five years, the city has handled 150 million complaints from citizens, achieving a resolution rate of 96.5 percent and a satisfaction rate of 96.9 percent.
The attendees have been invited to visit the Beijing 12345 Citizen Hotline Service Center on the sideline of the forum, to gain firsthand insights into Beijing’s exploration and innovation in the governance of mega-cities.
Sponsored by the Chinese Academy of Social Sciences, China Media Group, Communist Party of China Beijing Municipal Committee and the People’s Government of Beijing Municipality, the forum has a main forum and six parallel sessions.
Photo – https://mma.prnewswire.com/media/2584884/image1.jpg
Photo – https://mma.prnewswire.com/media/2584885/image2.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cctv-2024-beijing-forum-on-swift-response-to-public-complaints-opens-in-beijing-302335767.html
Agreement reached on acquisition of Sonoco’s TFP business as TOPPAN Group accelerates expansion of sustainable packaging business in Americas
TOKYO, Dec. 19, 2024 /PRNewswire/ — TOPPAN Holdings Inc. (TYO: 7911) (TOPPAN Holdings) has entered into an agreement with Sonoco Products Company (NYSE: SON) (Sonoco), a global leader in high-value sustainable packaging, to acquire Sonoco’s Thermoformed & Flexible Packaging (TFP) business for approximately $1.8 billion on a cash-free and debt-free basis and subject to customary adjustments.
This acquisition is highly complementary, combining the robust sales network, customer base, and solution development capabilities of Sonoco’s TFP business in North and South America with the technical expertise and manufacturing capabilities of TOPPAN Group’s global packaging business.
Sonoco’s TFP is a leading thermoformed and flexible packaging business serving a wide range of customers in food, retail, and medical verticals. TFP provides a variety of complex packaging to value-added categories including snacks, condiments, healthcare, prepared meals, fresh products, coffee, and pet food. On a pro forma standalone basis, TFP had revenue of approximately $1.3 billion in 2023.
“We are extremely pleased to have the opportunity to bring Sonoco’s TFP business to the TOPPAN Group. In order to accelerate our strategy to become a global leader in sustainable packaging solutions, we will employ the complementary strengths of both parties to drive growth, solve customers’ needs and create significant value for our shareholders,” said Hideharu Maro, Representative Director, President & CEO of TOPPAN Holdings. “This is an essential milestone in the TOPPAN Group’s global strategy to scale the sustainable packaging business.”
This transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first half of 2025.
The TOPPAN Group’s Strategy
The TOPPAN Group aims to be a leading solution provider addressing global issues. Under the current medium-term-strategy, the TOPPAN Group has been transforming its portfolio, and one of its key strategies is to drive sustainable packaging solutions at global scale.
The vision of the TOPPAN Group’s packaging business is “Change the World through Packaging Innovation,” and its mission is to “Foster a society focused on well-being and sustainability, while safeguarding our planet for future generations, through the continuous development of innovative packaging solutions that explore cutting-edge materials and technologies.”
The TOPPAN Group has been driving innovation in the development of sustainable packaging solutions by establishing a global supply chain from film manufacturing to packaging manufacturing and optimizing cost to meet brand owners’ needs locally and globally.
Advisors
Houlihan Lokey is acting as lead financial advisor and Morrison & Foerster LLP is acting as legal advisor to TOPPAN. Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. is also acting as financial advisor to TOPPAN.
Goldman Sachs & Co. LLC is acting as lead financial advisor and Freshfields LLP is acting as legal advisor to Sonoco. RBC Capital Markets, LLC is also acting as financial advisor to Sonoco.
About the TOPPAN Group
Established in Tokyo in 1900, the TOPPAN Group is a leading and diversified global provider committed to delivering sustainable, integrated solutions in fields including printing, communications, security, packaging, décor materials, electronics, and digital transformation. The TOPPAN Group’s global team of more than 50,000 employees offers optimal solutions enabled by industry-leading expertise and technologies to address the diverse challenges of every business sector and society and contribute to the achievement of shared sustainability goals.
https://www.holdings.toppan.com/en/
https://www.linkedin.com/company/toppan/
About Sonoco’s TFP
Sonoco’s TFP business has a strong customer base and manufacturing footprint in North America and South America with approximately 4,500 employees in 22 manufacturing plants, over 700 patents, and design capability across 10 countries.
Logo – https://mma.prnewswire.com/media/2584831/logo_blue_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/toppan-holdings-acquires-sonocos-tfp-business-302335693.html
WASHINGTON, Dec. 19, 2024 /PRNewswire/ — The global law firm Jones Day announces that the 37 lawyers listed below will be admitted to the Firm’s partnership effective January 1, 2025.
“This class of new partners once again reflects Jones Day’s ability to provide our valued clients the guidance and legal solutions for their most complex business challenges across the globe,” said Gregory M. Shumaker, Managing Partner of Jones Day.
The full announcement is also available on Jones Day’s website. The list follows:
- Rebecca Wernicke Anthony, Business & Tort Litigation, Dallas
- Matthew Barrett, Corporate, London
- Joseph C. Barry, Financial Markets, Cleveland
- Irina K. Bleustein, Securities Litigation & SEC Enforcement, Washington
- Mathis Bredimus, Corporate, London
- Kelsey S. Bryan, Business & Tort Litigation, Los Angeles
- Emily W. Cai, Corporate, New York
- Diana L. Calla, Business & Tort Litigation, San Francisco
- Andrew J. Clopton, Issues & Appeals, Detroit
- Arturo de la Parra, Financial Markets, Mexico City
- Adrien Descoutures, Corporate, Paris
- Preslava Dilkova, Government Regulation, Brussels
- Amanda L. Dollinger, Financial Markets, New York
- Anna A. Dwyer, Real Estate, Chicago
- Justin P. Farra, Corporate, Columbus
- Matthew J. Gherlein, Financial Markets, Cleveland
- Fabio Maria Guidi, Financial Markets, Milan
- Ryan Harmanis, Business & Tort Litigation, Columbus
- Jared P. Hasson, Corporate, Cleveland
- Andrew D. Iammarino, Financial Markets, Cleveland
- Kurt A. Johnson, Detroit, Issues & Appeals
- Andrew J. Junker, Business & Tort Litigation, Dallas
- Thomas S. Koglman, Intellectual Property, Cleveland
- Laura E. Koman, Health Care & Life Sciences, Washington
- Marta Lahuerta Escolano, Government Regulation, Paris
- Justin D. Martin, Labor & Employment, Miami
- Alexander V. Maugeri, Government Regulation, New York
- Justin W. McKithen, Financial Markets, Atlanta
- Karl S. Moussalli, Global Disputes, London
- Victoria Cuneo Powell, Business & Tort Litigation, Atlanta
- Gabrielle E. Pritsker, Business & Tort Litigation, Washington
- Kaitlinn P. Sliter, Corporate, Chicago
- Bijan Tavakoli, Government Regulation, Frankfurt
- Jessica Tierney, Health Care & Life Sciences, Washington
- Collin L. Waring, Real Estate, Dallas
- Ann-Marie Woods, Labor & Employment, Chicago
- Jason Z. Zhou, Business & Tort Litigation, Chicago
Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents. The Firm is distinguished by: a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
Photo – https://mma.prnewswire.com/media/2584725/Jones_Day_New_Partners.jpg
View original content:https://www.prnewswire.co.uk/news-releases/jones-day-names-37-new-partners-302335622.html
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief (Nuvei, Google, Upvest, Gen Digital, MoneyLion)
-
Fintech2 days agoFintech Pulse: Your Daily Industry Brief (Synapse, Shenzhen Institute, Visa, AutomatIQ, MeridianLink)
-
Fintech PR6 days agoCathay Financial Holdings Calls for Climate Finance Mobilization to Drive the Climate Industrial Revolution
-
Fintech PR6 days agoA New Era of $WUSD — Revolutionizing Stablecoins with Unmatched Security, Stability and Next-Gen Innovation
-
Fintech PR5 days agoLanistar launches new gaming sites in Brazil as secures right to operate pending final approval on its licence
-
Fintech PR6 days agoHealthcare Revenue Cycle Management (RCM) Market Surges to USD 658.7 Billion by 2030, Propelled by 24% CAGR – Verified Market Reports®
-
Fintech1 day agoFintech Pulse: Your Daily Industry Brief (Revolut, Bestow, Advyzon, Tyme Group, Nubank)
-
Fintech PR6 days agoInternational Communication Forum: Pathways To A Sustainable Future